Molecular Docking Studies with Rabies Virus Glycoprotein to Design Viral Therapeutics

被引:14
作者
Tomar, N. R. [1 ]
Singh, V. [1 ]
Marla, S. S. [1 ]
Chandra, R. [2 ]
Kumar, R. [3 ]
Kumar, A. [1 ]
机构
[1] GB Pant Univ Agr & Technol, Dept Mol Biol & Genet Engn, Pantnagar 263145, Uttar Pradesh, India
[2] GB Pant Univ Agr & Technol, Dept Vet Microbiol, Pantnagar 263145, Uttar Pradesh, India
[3] Cent Sheep & Wool Res Inst, Anim Biotechnol Sect, Avikanagar 304501, India
关键词
Docking; glycoprotein; molecular operating environment; polyethylene glycol 4000; rabies; RVG; RECEPTOR;
D O I
10.4103/0250-474X.73905
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The genome of rabies virus encodes five proteins; the nucleoprotein, the phosphoprotein, the matrix protein, the glycoprotein, and the RNA-dependent RNA polymerase. Among these, the glycoprotein is the most important as it is the major contributor to pathogenicity and virus neutralizing antibody response. Keeping in mind that glycoprotein is the only protein exposed on the surface of virus and is thought to be responsible for the interaction with the cell membrane, it was attempted to target glycoprotein by a ligand polyethylene glycol 4000, which blocks its active site, as seen by molecular operating environment software, so that it may be possible to prevent the spread of virus into the host. The ligand polyethylene glycol 4000 was retrieved from Research Collaboratory for Structural Bioinformatics protein data bank by providing the glycoprotein sequence to the databank. In this study it was observed that the ligand was successfully docked on a major portion of antigenic site II of glycoprotein by mimicking the virus neutralizing antibodies. This knowledge may be important for the development of novel therapies for the treatment of rabies and other viral diseases in the future.
引用
收藏
页码:486 / 490
页数:5
相关论文
共 12 条
  • [1] *CHEM COMP GROUP I, 2005, MOE MOL OP ENV VERS
  • [2] MOLECULAR-CLONING AND COMPLETE NUCLEOTIDE-SEQUENCE OF THE ATTENUATED RABIES VIRUS SAD-B19
    CONZELMANN, KK
    COX, JH
    SCHNEIDER, LG
    THIEL, HJ
    [J]. VIROLOGY, 1990, 175 (02) : 485 - 499
  • [3] BIOLOGICAL CHARACTERIZATION OF HUMAN MONOCLONAL-ANTIBODIES TO RABIES VIRUS
    DIETZSCHOLD, B
    GORE, M
    CASALI, P
    UEKI, Y
    RUPPRECHT, CE
    NOTKINS, AL
    KOPROWSKI, H
    [J]. JOURNAL OF VIROLOGY, 1990, 64 (06) : 3087 - 3090
  • [4] Dietzschold B., 1996, FIELDS VIROLOGY, V3rd, P1137
  • [5] DODET B, 2001, EXECUTIVE SUMMARY RA, P191
  • [6] Spread and pathogenic characteristics of a G-deficient rabies virus recombinant:: an in vitro and in vivo study
    Etessami, R
    Conzelmann, KK
    Fadai-Ghotbi, B
    Natelson, B
    Tsiang, H
    Ceccaldi, PE
    [J]. JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 2147 - 2153
  • [7] EVIDENCE FROM THE ANTIIDIOTYPIC NETWORK THAT THE ACETYLCHOLINE-RECEPTOR IS A RABIES VIRUS RECEPTOR
    HANHAM, CA
    ZHAO, F
    TIGNOR, GH
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (01) : 530 - 542
  • [8] Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites
    Laurie, ATR
    Jackson, RM
    [J]. BIOINFORMATICS, 2005, 21 (09) : 1908 - 1916
  • [9] Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery
    Mazarakis, ND
    Azzouz, M
    Rohll, JB
    Ellard, FM
    Wilkes, FJ
    Olsen, AL
    Carter, EE
    Barber, RD
    Baban, DF
    Kingsman, SM
    Kingsman, AJ
    O'Malley, K
    Mitrophanous, KA
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (19) : 2109 - 2121
  • [10] A MODEL OF THE RABIES VIRUS GLYCOPROTEIN ACTIVE-SITE
    RUSTICI, M
    BRACCI, L
    LOZZI, L
    NERI, P
    SANTUCCI, A
    SOLDANI, P
    SPREAFICO, A
    NICCOLAI, N
    [J]. BIOPOLYMERS, 1993, 33 (06) : 961 - 969